WELCOME to epgonline.org

Access trusted, independent sources of clinical content for the United Kingdom as well as other regions. Registration is quick and simple, providing you with unlimited access to all content and features.
 

Latest News

Added 11 hours ago Drug news

FDA approves Actemra (tocilizumab) subcutaneous injection for the treatment of giant cell arteritis.- Genentech/Roche

Genentech, a member of the Roche Group , announced that the FDA has approved Actemra (tocilizumab) subcutaneous injection for the...

Added 11 hours ago Drug news

Phase III study of Latuda (lurasidone HCI) shows statistically significant improvement in bipolar disorder- Sunovion Pharma

Sunovion Pharmaceuticals announced that results of a Phase III clinical study evaluating Latuda (lurasidone HCI) in children and adolescents (10...

Added 11 hours ago Drug news

Phase III ZONDA trial of MEDI 563 (benralizumab) meets primary endpoint in asthma and is published in NEJM- AstraZeneca

Results from the Phase III ZONDA trial of MEDI 563 (benralizumab), from AstraZeneca, demonstrated that adding benralizumab to standard of...

View all news articles

WHAT'S ON THE HORIZON?

Marshall Pearce

Cancer immunotherapies

Posted 1 month ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 1 month ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Latest Journal Abstracts

Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.

Oral palbociclib (Ibrance®) is a first-in-class, highly selective inhibitor of cyclin-dependent kinases 4 and 6 (i.e. a CDK4/6 inhibitor). It is indicated for the treatment of women with HR-positive, HER2-negative ...

Added 5 hours ago

Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.

Introduction: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody ...

Added 6 hours ago

Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?

Human eosinophils represent approximately 1% of peripheral blood leukocytes. However, these cells have the propensity to leave the blood stream and migrate into inflamed tissues.

Added 6 hours ago

View all journal articles

Latest Guidelines

American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis.

The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees.

Added 2 months ago

GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD.

Since 2001, the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease has been a valuable resource for healthcare professionals.

Added 12 days ago

Psoriasis overview NICE Pathways

This document contains a single pathway diagram and uses numbering to link the boxes to the associated recommendations.

Added 3 months ago

View all guidelines

Latest Clinical Trials

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

This study involves a course of radiation to up to 5 tumors in the participant's liver followed by systemic therapy (Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body).

Added 1 month ago

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA)...

Added 3 months ago

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added 3 months ago

View all clinical trials